TransMed7

Accuracy - the Crucial Factor

Accuracy — with Precision, Control, Effortless Penetration, Capture, Transport — the hummingbird is nature’s most skillful surgeon. TransMed7’s Zero5 technology leverages these principles to unlock the power of repeatable access to every area of the body to remove, reveal, deliver or replace. Enter the new frontier.  

Zero5

SpeedBird

Concorde

Cardinal

ABOUT

Who We Are
And What We Do

TransMed7 is a privately-held medical technology company founded in 2010 to generate transformational technologies for diverse fields of healthcare around the world.

We are focused on the highly efficient development of innovative, cost effective, minimally invasive medical devices via several project companies with a particular focus in oncologic, regenerative, and cardiovascular disease.

Our products are designed to address critical healthcare needs in medical fields such as: breast health; soft tissue surgery, including small or fragile tissues and difficult to access areas; endoscopy, laparoscopy, robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.

News & Announcements

TransMed7, LLC Announces First Revenue from Concorde Family of Devices

TransMed7, LLC Announces First Revenue from Concorde Family of Devices

Portola Valley, CA, September 6, 2023 – TransMed7, LLC announced today the first sales of Concorde (Single Insertion…
TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch

TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch

Portola Valley, CA, February 6, 2023 – TransMed7, LLC announced today that the “First in Human” series of…
TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch

TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch

Portola Valley, CA, August 16, 2022 – TransMed7, LLC announced today that the “First in Human” clinical case…
TransMed7, LLC Announces First Clinical Use of SpeedBird™ Breast Biopsy Devices for Commercial Launch

TransMed7, LLC Announces First Clinical Use of SpeedBird™ Breast Biopsy Devices for Commercial Launch

Portola Valley, CA, August 8, 2022 – TransMed7, LLC announced today that the first clinical cases of the…

Want to Know More?

For further information on TransMed7 and its platform technologies,
please reach out to us using the form below.
Scroll to Top